Podcasts about Barata

¿La gent és insuportable? Crítica de la minisèrie «Sala polivalent». Guió: Joan Yago i Israel Solà. Sèrie audiovisual de la companyia La Calòrica. Intèrprets principals: Xavi Francés, Aitor Galisteo-Rocher, Esther López, Marc Rius, Israel Solà, Júlia Truyol i Joan Yago. Intèrprets convidats al llarg dels sis episodis: Roser Batalla, Dario Bellusci, Nicolás Carbajal, Oriol Casals, Lulu Cormican, Marc Domingo, Miriam Moukhles, Tamara Ndong, Francesca Piñón, Olivia Rius, Kathy Sey, Ireneu Tranis i Teresa Vallicrosa. Productor executiu creatiu: Ivan Mercadé. Productors executius de Filmax: Carlos Fernández i Laura Fernàndez Brites. Cap de continguts digitals 3Cat: Adrià Serra. Productora executiva continguts digitals 3Cat: Anna López. Producció executiva 3Cat: Oriol Sala-Patau i Conxa Orea. Productora delegada Filmax: Teresa Gefaell. Direcció producció: Alejandro Torroja. Directora fotografia: Agnès Piqué Torroja. Directora d'art: Evelin Hernández. Cap de maquillatge: Carla Casals. Cap de perruqueria: Samuel Fernández. Cap de vestuari: Néstor Reina. Cap de so: Mar Almansa. Muntador: Alex de Molina. Composició i veu : Guillem Rodríguez. Coregorafia voguing: Israel Solà. Direcció de postproducció: Francisco Mejuto. Edició de continguts 3Cat: Joan Marí de la Fuente. Realització 3Cat: Laura Serra. Ajudants de direcció: Clàudia Aragón i Gràcia Mata de la Barata. Script: Natalia Vicente. Lingüista: Ignasi Oliver. Departament de produccio: Silvia S. Lasarcos, Marta Tabaras, María G. Periñán, Miquel Falcó, Jordi Llorca (Filmax). Departament legal: Marta Alonso i Sergi Miravet. Caixera pagadora: María Postigo. Foquista: Ana Ferrón. Auxiliar de càmera: Magda Verdú. Vídeoassist: Amaia Marcos. Foto fixa: Marta Fernández. Operador segona càmera: Pablo Paloma. Foquistes segona càmera: Esther Mestres i Arkaitz de la Torre. Auxiliar de càmera: Júlia Jané. Ambientadora: Talissa Lopes. Attrezzistes de muntatge: Francisco Bosio i Luisa Álvarez. Reforç attrezzista de muntatge: Cristina Borda. Ajudant de maquillatge i perruqueria: Henar Rodríguez. Reforç de maquillatge: Julia Pastor. Ajudant de vestuari: Paula Velasco. Cap maquinista: Pol Tarrats. Gaffer: María González. Elèctrics: Daniel de José, Jordi Sánchez i Carlos Román. Assistent de muntatge: Núria Guillén. Subitulació i transcripcions: TakeMaker Studio. Grafisme i animació: Lavanda Pur i Òscar Martínez. Ajudant de postproducció i muntador promocional: Gerard Martí. Estudi postproducció de so: La Fábrica de Carbón. Edició de diàlegs: Daniel Miranda. Disseny de so i mescles: Pablo Martín. Supervisió de so: Quique López. Estudi postroducció imatge: Moonlight. Colorista: Ignasi González Insa. Assistent colorista: Sergio Porras. Masterització: Xavi Cortina. Director tècnic: Alejandro Matus. Productor: Marc Rosés. Producció de 3Cat i Arca Audivisual. Direcció de la sèrie: Joan Yago i Israel Solà (La Calòrica). Exclusiva Plataforma digital 3Cat. Estrena 1a temporada: 3 març 2025. Veu: Andreu Sotorra. Música: Tot és part de ser un pirata. Interpretació: El Pony Pisador. Composició: El Pony Pisador. Àlbum: El Popy Petit, 2024.

00:00 Aprovação de Lula desaba00:22 Adeus à Lula impulsiona Ibovespa00:38 Mercado comemora queda de Lula00:50 O que o Lula vai fazer agora?01:30 Ibovespa01:53 Ações02:47 Eleições 202603:39 Contas Pública | Rombos Fiscais04:42 Dívida Pública05:24 Taxa de Juros | Selic 06:24 Bolsa de Valores | B3 07:47 Velocímetro do Sentimento da Bolsa08:08 A Bolsa está Barata?08:38 Consultoria de Investimentos

Neste MP3 Especial de Celebração de 30 anos da escstunis, o Bernardo conversa com Compê, Aguilera e Onde sobre o que é pertencer à escstunis, como foram os seus percursos e que memórias guardam. Tudo isto acompanhado por músicas do seu reportório que são bastante familiares para quem os acompanha. Um episódio que celebra o passado e o presente da escstunis! Não vais querer perder! Se te quiseres juntar à celebração do trigésimo aniversário da escstunis, entra no link abaixo para comprares bilhetes para o espetáculo "Metamorfose em Palco" que irá ocorrer no dia 15 de fevereiro no Auditório Vitor Macieira LINK: https://tr.ee/3cHCxw3T1B Design: Vasco Fonseca e Bernardo Santos Sonoplastia: Alexandre Boavida

La nueva inteligencia artificial china redefine todo lo que sabíamos hasta la fecha del sector.

DeepSeek promete ser la alternativa más barata a OpenAI, pero ¿realmente está al mismo nivel? Analizamos si esta AI es una copia o una revolución, qué tan segura es usarla y qué significa para el futuro de la inteligencia artificial.  ¿Estamos ante una nueva potencia en AI o simplemente otro intento de China por controlar la tecnología? ⏰ Minutos  (0:59) ¿DeepSeek es realmente mejor?(1:28) ¿Es seguro usar DeepSeek?(3:04) ¿Triunfa el modelo Open Source?(6:22) ¿Se recupera Nvidia?(9:20) El poder político de la AI(9:50) El miedo de DeepSeek(10:40) Ventajas de DeepSeek(11:40) Democratización y desmonetización(12:46) Creatividad sobre presupuesto

Inteligencia Artificial, Donald Trump, Criptomonedas

Presentación de un nuevo Podcast, ANGELES CUSTODIOS: https://www.ivoox.com/ac-los-heroes-orzan-audios-mp3_rf_138887389_1.html Más en la mejor red de podcast del mundo entero SOSPECHOSOS HABITUALES: https://www.ivoox.com/podcast-red-sospechosos-habituales_sq_f1564393_1.html El CustomPC de Dani: https://www.youtube.com/watch?v=DV3MPC8Gn2U&themeRefresh=1 Más en CACHARREOGEEK: https://www.youtube.com/results?sp=mAEB&search_query=CACHARREOGEEK ENERGÍA BARATA, Canal de Telegram con mucha y buena información: https://t.me/GrinchOctopusEnergia Enlace de OCTOPUS por si os animáis a pasaros a ésa comercializadora y compartimos un cupón de 100€ a medias. 50€ para cada uno. ¡Muchas gracias por adelantado! Usa este código para registrarte en Octopus - https://share.octopusenergy.es/ideal-shale-317 SI EL ENLACE TE DA ERROR ESPERA UNOS DÍAS QUE ME ACABO DE CAMBIAR Y TIENEN QUE TRAMITARLO.

Presentación de un nuevo Podcast, ANGELES CUSTODIOS: https://www.ivoox.com/ac-los-heroes-orzan-audios-mp3_rf_138887389_1.html Más en la mejor red de podcast del mundo entero SOSPECHOSOS HABITUALES: https://www.ivoox.com/podcast-red-sospechosos-habituales_sq_f1564393_1.html El CustomPC de Dani: https://www.youtube.com/watch?v=DV3MPC8Gn2U&themeRefresh=1 Más en CACHARREOGEEK: https://www.youtube.com/results?sp=mAEB&search_query=CACHARREOGEEK ENERGÍA BARATA, Canal de Telegram con mucha y buena información: https://t.me/GrinchOctopusEnergia Enlace de OCTOPUS por si os animáis a pasaros a ésa comercializadora y compartimos un cupón de 100€ a medias. 50€ para cada uno. ¡Muchas gracias por adelantado! Usa este código para registrarte en Octopus - https://share.octopusenergy.es/ideal-shale-317 SI EL ENLACE TE DA ERROR ESPERA UNOS DÍAS QUE ME ACABO DE CAMBIAR Y TIENEN QUE TRAMITARLO.

Convidámos o médico Themudo Barata para falar connosco sobre a importância da prática de exercício físico ao longo da vida. Onde e quando devemos incluir o desporto na nossa semana?

El psicólogo José Antonio Galiani analiza el fenómeno de la “infoxicación” y sus efectos en la ansiedad y el bienestar emocional

El catedrático analiza la paradoja de España: indicadores macro por encima de nuestros vecinos europeos, sin que los españoles lo noten en su día a día.

# PATROCINADORES NESSE EPISÓDIO # KAPIBARA Softwares https://kapibara.com.br/ # ACOMPANHE NOSSA GAMEPLAY AO VIVO # YOUTUBE: https://www.youtube.com/canaldorickyzin TWITCH: https://www.twitch.tv/canaldoricky RPG DO TOCA | Apoie essa ideia divulgando esse EP do seu podcast favorito! #RPG #FALLOUT #Fallout2 #Fallout3 #Fallout4 #NewVegas #FalloutNewVegas #DieselPunk #NukaToca #Kapybara FICHA TÉCNICA: UNIVERSO: Nuka Toca (FALLOUT) SISTEMA: TocaSystem (D12) TEMÁTICA: Apocalipse Diesel Punk # JOGADORES # Lucas Wicktor (Johnatan Carvalho) DESCONHECIDO / Refúgio 82. Maximilian Redfield (Paulo Deros Elve) R.I.P Omar Karroten (Dr. XGB - "O Cenourão") DESCONHECIDO / Nova Vegas (???) Abel Lehnsherr (Leo di Paula) VIVO Vlad T. Vania (Rodrigo Silva) R.I.P R-66Y (Rodrigo Silva) OPERACIONAL Entregador 17 (Jorge Canelas) VIVO Supa (Wilkson Carvalho) VIVO Kafka Darksting (Heron Teixeira) VIVO # MESTRE # Ricky, O Bardo e seu fanatismo por FALLOUT e MAD MAX numa mistura muito louca! # PIX para que o Toca traga ainda mais RPG pra você! # Só mandar qualquer valor, o importante é ajudar para o nosso e-mail através do seu banco no método de transferência PIX: tocadodragaopodcast@gmail.com # SEJA UM APOIADOR # Os Power Rangers são os apoiadores do Toca, se tornando um você ganha uma Cor única e Um Megazord Especial, além de poder participar do grupo Fechado dos Power Rangers do Toca, escolhendo o tema de episódios e sabendo tudo que acontece nos bastidores do seu podcast favorito! Apoie com doações a partir de R$ 5,00 https://www.catarse.me/pt/atocadodragao # PATROCINE O PODCAST # Você tem uma Empresa, que tal patrocinar um Podcast extremamente promissor ainda em seu início? Ganhe mais visibilidade da sua marca e produto e receba chamadas em todos os Episódios com o melhor do Merchan, além de outras vantagens, entre em contato através do nosso e-mail: tocadodragaopodcast@gmail.com

Valora el hecho de que tengamos una fe clara y viva en el misterio de Dios Uno y Trino porque su costo fue la sangre de Nuestro Señor Jesucristo; no permitas que se pierda, al contrario que sea vida en tu vida.

The UROONCO RCC editorial board chief editor Dr. Carmen Mir, and associate editors Dr. Teele Kuusk and Dr. Riccardo Bertolo share highlights of the important kidney cancer developments for 2024. They summarise the results on several important trials such as FASTRACK, ZIRCON, KEYNOTE-564 and IMmotion010. They also discuss the developments on surgical aspects too.To learn more on the highlights discussed in this podcast, you can read the below Articles of the Month, listen to the podcasts or watch the videos.Stereotactic ablative body radiotherapy for primary kidney cancer (TROG 15.03 FASTRACK II): a non-randomised phase 2 trial[89Zr]Zr-girentuximab for PET–CT imaging of clear-cell renal cell carcinoma: a prospective, open-label, multicentre, phase 3 trialASCO GU24 special: Assoc. Prof. Barata discusses the results of KEYNOTE-564 and CheckMate-914ASCO GU24 special: Prof. Michael Hofman talks about a novel CA IX-targeting peptideASCO2024 special: Circulating kidney injury molecule-1 biomarker analysis in IMmotion010Present and future of robotic surgery for RCCThe treatment of locally advanced and metastatic renal cancerFor more EAU podcasts, please go to your favourite podcast app and subscribe to our podcast channel for regular updates: Apple Podcasts, Spotify, Google Podcasts.

A reta final de 2024 é marcada por baixa nos preços do feijão. Aqueles considerados nobres, colhidos nesta época do ano, têm sido comercializados na faixa dos R$260. Por outro lado, um fato que traz esperança aos produtores brasileiros é que as indústrias encerraram os trabalhos em dezembro com estoques vazios. Sendo assim, a volta ao mercado em janeiro será com compras intensas. Podemos então afirmar que o feijão terá uma forte alta no começo de 2025? O presidente do IBRAFE, Marcelo Lüders, adota cautela. Segundo ele, também haverá a entrada de mercadoria para venda, o que deve impedir uma disparada. Mas sim, é esperada uma valorização para o mês de janeiro.

Siga, curta, se inscreva, compartilhe nossas redes sociais. Basta tocar aqui https://linktr.ee/ipcaltamira"Todo ser que respire louve ao Senhor" Salmos 150:6Gravado dia 15 de dezembro de 2024 na Igreja Presbiteriana Central de Altamira/PA.IntegrantesVozes: Thais, Ingrid, MateusMúsicos: Murilo Baixo, Ricardo Bateria, Tiago Violão, Sax Mateus SousaDireitos autorais da música, letra pertence aos artistas originais e gravadoras.Somos a Igreja Presbiteriana Central de Altamira/PA.O templo fica localizado à Rua Gov. Magalhães Barata, 465 - Centro, Altamira - PA, 68371-075, faça-nos uma visita.Nosso compromisso é com a palavra de Deus, única e verdadeira para todo o sempre amém. Que Deus possa alcançar onde você estiver.

El cocinero malagueño que pocos días después de conseguir la tercera estrella Michelin para el restaurante marbellí que llevaba su nombre sorprendió anunciando que  lo cerraría para convertirlo en una casa de carnes a la parrilla, reflexiona sobre cómo vivió aquellos días, por qué tomó esa decisión y cómo con el tiempo ha ido asumiendo la transformación de su nombre y apellidos en una marca.

El economista José Antonio Herce propone expandir el consorcio de Muface al resto de España, ya que, sostiene, sería más barato para todos

Mensagem de 17 de Novembro de 2024 de Carolina Barata com o titulo "O Valor da Obediência".

En el programa de hoy, te mostraremos que sí hay una forma más inteligente de comprar tu primera casa ¡No te lo pierdas!

A esta hora avanza una protesta de cultivadores de cebolla cabezona en Bogotá, provenientes del departamento de Boyacá con el fin de exigir más garantías con respecto a su marcado y economía.See omnystudio.com/listener for privacy information.

Dejamos nuestro último episodio preguntándonos sobre los costos de construir una casa con derivados de la arcilla. ¡Resulta que es barato! Entonces, si es barato, ¿más personas han aprovechado la oportunidad de construir de esta manera? y ¿por qué no se ha popularizado en entornos urbanos? Para responder a estas preguntas, continuamos la conversación con Miguel Ángel Pérez, un bioconstructor de Baja, y hablamos sobre los costos de la construcción con arcilla. Tambien charlamos con Rachel Formanek, una neoyorquina que se mudó de California a Baja para encontrar condiciones de vida mejores y más asequibles. Por último, nos sentamos con Alex Ruiz, director de planificación urbana en Tecate y nos dió una nueva perspectiva sobre la viabilidad de la construcción con tierra en entornos urbanos. Foto de portada: Carlos Jaime and Cuahtémoc Herrera Sobre la temporada 6 Port of Entry tiene una nueva temporada con más historias de nuestra región fronteriza. En esta ocasión, estamos mostrando las perspectivas de algunos moldeadores y visionarios de las tierras fronterizas. Te contamos historias de personas que están impactando la región, y en algunos casos, el mundo con su trabajo e investigación; desde urbanismo hasta arquitectura, educación y política, y hasta arte y robótica. ¡Escucha nuestra nueva temporada! Redes sociales y contacto De KPBS, Port of Entry cuenta historias que cruzan fronteras. Para escuchar más historias visita www.portofentrypod.org Facebook: www.facebook.com/portofentrypodcast Instagram: www.instagram.com/portofentrypod Puedes apoyar nuestro podcast en www.kpbs.org/donate, escribe en la sección de regalos (gift section) “Port of Entry” y como agradecimiento podrás recibir un regalo. Si tu empresa u organización sin fines de lucro desea patrocinar nuestro podcast, envía un correo a corporatesupport@kpbs.org Nos encantaría recibir tu retroalimentación, envíanos un mensaje al 619-500-3197 o un correo a podcasts@kpbs.org con tus comentarios y/o preguntas sobre nuestro podcast. Créditos Hosts: Alan Lilienthal y Natalie González Escritor/Productor: Julio C. Ortiz Franco Productor Técnico/Diseñador Sonoro: Adrian Villalobos Productora Técnica: Rebecca Chacon Editora: Elma Gonzalez Lima Brandao y Melissa Sandoval Episodios traducidos por: Natalie González, Julio C. Ortíz Franco y Melissa Sandoval Directora de Programación de Audio y Operaciones: Lisa Morrisette This program is made possible, in part, by the Corporation for Public Broadcasting, a private corporation funded by the American people

Convidado desta edição, Carlos Takahashi, chairman da BlackRock no Brasil, revela por que o Brasil está atrás na corrida pelos recursos dos grandes investidores externos. Entre os Touros e Ursos da semana, a Enel e o novo apagão em São Paulo, a SpaceX de Elon Musk e os vencedores do Nobel de Economia.

Mensagem do dia 29 de Setembro de Carolina Barata com o título "Uma Chamada para a Retidão".

El textil y la tecnología son lo  más demandado entre los consumidores

O que as mentes que estão por trás dos investimentos das famílias mais ricas do Brasil pensam sobre o momento atual do mundo e das oportunidades? E sobre os riscos? Esse foi o bate-papo que tivemos com o comitê de investimento do VRB Impacto, uma casa de alocação de recursos com fins filantrópicos, com mais de 20 milhões de reais doados a sociedade. No comitê, os responsáveis pela área de investimento dos principais escritórios familiares do país. Que definem onde as fortunas são destinadas, onde moram as grandes oportunidades de investimento.Foi a primeira vez na história que o comitê inteiro do VRB se reuniu num painel. Você não pode perder essa, aperta o play!Apresentação: Lucas CollazoDireção e edição: Nando LimaImagens: Nando Lima, Thiago Vianna, Anderson LuizCaptação de áudio: Today EntretenimentoRedes sociais: Olavo Granado

No podcast ‘Notícia No Seu Tempo', confira em áudio as principais notícias da edição impressa do jornal ‘O Estado de S.Paulo' desta quarta-feira (14/08/2024): Embutidos na conta de luz paga pelo consumidor, subsídios a setores como usinas térmicas a carvão e energias eólica e solar alcançaram R$ 40,3 bilhões em 2023 e ajudam a explicar por que o Brasil é o país da eletricidade barata e da tarifa alta. Hoje, esses incentivos representam 13,5% da fatura mensal, ante 5,5% em 2018. “O nosso custo de geração de energia está entre os mais baixos do mundo, mas nossa conta de luz é uma das que mais pesam no bolso do consumidor”, afirma Katia Rocha, pesquisadora do Instituto de Pesquisa Econômica Aplicada (Ipea). De acordo com a Associação Nacional dos Consumidores de Energia (Anace), o preço da energia no mercado regulado – o modelo mais comum para residências – subiu 61% nos últimos 11 anos. Já a tarifa média no País saltou 153% no mesmo período.  E mais: Economia: Avança a taxa sobre plano de previdência deixado como herança Internacional: Lula sugere uma nova eleição para superar crise política na Venezuela  Política: Lei dá brecha e candidatos com menor tempo de TV apostam em podcasts Metrópole: Após queda, Voepass cancela voos de Fernando de Noronha Esportes: ‘Medalha resgata o respeito pela seleção', diz MartaSee omnystudio.com/listener for privacy information.

As notícias de hoje incluem um hacker que conseguiu assumir remotamente o controle de uma usina de energia, a Samsung lançando uma TV gigante de 98 polegadas na sua linha mais barata de 2024 e a Google revelando oficialmente seus novos smartphones da família Pixel 9, incluindo um Fold, além de um smartwatch e fones de ouvido com recursos de IA que vão do sensacional ao ligeiramente assustador. Boa noite e bem-vindos ao Hoje no TecMundo, o seu resumo diário de tecnologia!

ACERCA DE LA SERIE: Los “cristianos light” no han comprendido realmente la esencia ni el enfoque de la Palabra de Dios. Esto así, ya que, muy posiblemente guiados por sus deseos de encontrar una “religión” o una “filosofía de vida” que se enfoque en la resolución de sus problemas y les proporcione la felicidad, a través de la prosperidad material, se desvían del sentido real de la Palabra de Dios que, en ningún lugar, nos dice que, al convertirnos en cristianos verdaderos, y caminar en las “huellas de Cristo” vamos a ser felices o prósperos.  La sana doctrina nos enseña que, cuando procuramos ser como Cristo, vamos a sufrir. De algo de lo que debemos estar bien claros es que la espiritualidad del cristianismo se robustece mediante una vida de sufrimiento. ACERCA DEL MENSAJE: Muchas personas, por la razón que sea, están mas interesados en las cosas pasajeras de aquí y no valoran el reino de los cielos, el reino que se ha acercado, por eso les resulta mas atractivo el mensaje de la gracia barata. Nuestros ojos deben estar puestos en Jesús y Su reino. En lo que perdura, no en lo efímero. El arrepentimiento es parte fundamental del mensaje del evangelio. Es la puerta de inicio a una relación con Dios. Audio MP3 Fecha:  11 de agosto , 2024 Autor: JJ Gómez

Nos visita Dario Z para filosofar en serio y ¿quién es la sexta silla del día?

Mensagem de Julho de 2024 de Carolina Barata com o Título "Se A Tua Presença Não For Connosco, Não Nos Faças Sair Daqui"

Ouça aqui a segunda parte da conversa em podcast com o filósofo, professor e investigador André Barata, que comenta sobre a constelação de perigos principais que nos ameaçam e revela onde encontra na atualidade, maior apoio, e inspiração para  a sua atividade de pensar, seja em autores ou obras, cujo aprofundamento possa contribuir para estar à altura do mundo. E ainda nos dá música e deixa várias sugestões culturais para este verão. Boas escutas!See omnystudio.com/listener for privacy information.

A inflação anual registrada em junho na Argentina mostra uma alta de quase 300% nos preços, isso significa que o que no ano passado custava 1.000 pesos hoje sai por cerca de 3.000. A moeda argentina segue se desvalorizando, mas num ritmo menos intenso do que ao fim de 2023. Ainda assim, a taxa de câmbio bateu 480 pesos por dólar. Seis meses após o início do governo de Javier Milei, o que realmente mudou? Hoje eu vim para a Argentina para explorar novamente a economia dos nossos vizinhos. Esse vídeo será dividido em duas partes. Primeiro, vamos falar da situação atual das taxas de câmbio e como isso está afetando os turistas. Será que a Argentina continua barata para os brasileiros? Na segunda parte, vamos falar sobre a situação do governo de Javier Milei. Ele está conseguindo aprovar as reformas? Elas estão melhorando a realidade do país? Como a população está sentindo as mudanças?

O filósofo André Barata anda há muito a refletir sobre a importância de desacelerarmos. Em 2018 lançou o livro “E se Parássemos de Sobreviver? — Pequeno Livro para Pensar e Agir contra a Ditadura do Tempo”, editado pela Documenta. Este professor catedrático na Universidade da Beira Interior (UBI), a dirigir atualmente a Faculdade de Artes e Letras, defende que há uma aceleração artificial do tempo que vem desde a Revolução Industrial e que ganhou ainda mais força na era digital. Nestas suas reflexões considera que a sociedade deve “sair da armadilha da sobrevivência", que o rendimento das pessoas não deve depender do trabalho e que ainda há muito para descolonizar sobre o passado português. Ouçam-no aqui nesta primeira parte da conversa com Bernardo Mendonça.See omnystudio.com/listener for privacy information.

Arroba do boi gordo deve se consolidar nos R$230 em SP e a demanda de pós férias em Agosto vai determinar novas altas

Dr. Pedro Barata and Dr. Lillian Siu discuss recent advances in cancer vaccines and biomarkers, including the potential of the neoantigen and immune modulatory vaccines and the challenges surrounding cancer vaccine development. TRANSCRIPT Dr. Pedro Barata: Hello, I'm Dr. Pedro Barata, your guest host for the ASCO Daily News Podcast today. I'm a GU medical oncologist at the University Hospitals Seidman Cancer Center in Cleveland, Ohio, and an associate professor of medicine at Case Western Reserve University School of Medicine. I'm also an associate editor of the ASCO Educational Book. And today we'll be discussing a timely article that was recently published in the Educational Book titled, “State-Of-The-Art Advancements on Cancer Vaccines and Biomarkers.”   I'm delighted to welcome one of the article's co-authors and a world-renowned oncologist, Dr. Lillian Siu. She is a senior medical oncologist and director of the Phase 1 Program at the Princess Margaret Cancer Center and a professor of medicine at the University of Toronto.  Welcome, Dr. Siu. Dr. Lillian Siu: Thank you, Dr. Barata; it's great to be here. Dr. Pedro Barata: Wonderful. Dr. Siu will discuss new tools for cancer vaccine development, strategies for combating the immunosuppressive and tumor microenvironment. She will also address cancer vaccine guidelines and patient recruitment strategies to optimize patient selection and access to cancer vaccine trials. I should say that Dr. Siu and her co-authors also addressed this topic during an Education Session at the ASCO 2024 Annual Meeting.  Finally, our full disclosures are available in the transcript of this episode.  So again, Dr. Siu, great to be speaking with you today. I'm looking forward to our discussion.  Dr. Lillian Siu: Thank you, Dr. Barata. And before I begin, I want to acknowledge Dr. Jeffrey Weber and Dr. Inge Marie Svane, who both presented during the ASCO session you mentioned. They gave excellent presentations related to the topic of neoantigen vaccines and immune-modulatory vaccines, which we will talk about later. Dr. Pedro Barata: Wonderful. So let's get started. Cancer vaccines are among the most promising frontiers for breakthrough innovations and new strategies in the fight against cancer. The successes in vaccine development during the COVID-19 pandemic, I think, inspired further research in this area. Why do you think it's important that we harness these recent successes and technological advances to really accelerate progress in vaccine development? Dr. Lillian Siu: Absolutely. I think all of us who have lived through COVID really appreciated how important the COVID vaccine development was to all of us. It saved millions of lives. And I think we witnessed a paradigm change in drug development that none of us thought was possible, that we're able to actually bring a concept to a drug from bench to bedside within an extremely short time. That timeline is not something we would ever imagine to have happened, and it did. And I think it gives us hope that perhaps this is not just limited to the COVID vaccine; it's also extrapolatable to other therapeutics – that we can bring promising medicines to our patients in a really expedited timeline, obviously without compromising their safety.  We now know that cancer vaccines have entered a new, or maybe I should say, renewed era of promise. And it's holding promise on many fronts, Pedro, if I may. It's very exciting in the area of molecular residual disease. In other words, a setting where the cancer is treated definitively by surgery or radiation, plus adjuvant treatment. And we know some patients will relapse because we know they're at high risk. And now we also have different ways to detect these microscopic risks, such as by ctDNA, circulating tumor DNA, or biomarkers. And we know that having some therapeutic that can eradicate these cancers at such microscopic levels would be very attractive, especially with low toxicity, and I think cancer vaccine is such a candidate. And of course, we can even look further into the future of using such treatment in cancer prevention, especially in those with high risk of developing cancer, for example, those with hereditary syndromes like lynch syndrome. We're not there yet, but I think it holds that promise.   So I think, going back to your original question, if we can develop such a therapeutic that is showing promise in a very short period of time, it brings the timeline and the hope to a much shorter timeframe to really deliver to our patients in a very timely manner while safeguarding all the important parts, such as safety and tolerability. Dr. Pedro Barata: Wow, those are such important points. I couldn't agree with you, more. It's really exciting. As I think through this, and as I was reading through your piece, I was thinking it would be great if you could highlight some of the novel approaches to personalized neoantigen vaccine development that are driving progress in this space. Dr. Lillian Siu: Absolutely. And during the session, Dr. Weber spoke about the neoantigen vaccine, and he's a pioneer in this space. So I can only try to iterate some of the points he had delivered during his talk. Neoantigen is a very exciting space for immunologists because we know that tumors express these neoantigens. Many of these are unique antigens that are only expressed in tumors, so-called tumor specific antigens, that we can use as our targets, including vaccines, but not limited to vaccines. And with these altered sequences in DNA in different forms, they could be mutations and splice alterations, etc. We expect that we have modified proteins that are expressed by tumor cells, and these become targets for our drug development of vaccines. And now we can have very specific strategies, very sophisticated algorithms to figure out which neoantigens are more so called immunogenic, more likely to stimulate or activate the immune system, and they can be recognized by T cells. So leveraging this knowledge and technology, we have been able to develop especially mRNA vaccines that are deliverable to our patients through different mechanisms, for example, in lipopeptides, etc., so that we can deliver to the patients in a safe way, such that we can use it to deliver vaccines, such as in the MRD setting that I mentioned earlier, as well as in the advanced disease setting. So Dr. Weber, in his presentation, highlighted one of such vaccines that have been tested in a randomized controlled trial that is KEYNOTE-942, which randomized 157 patients to the mRNA vaccine plus pembrolizumab versus pembrolizumab alone in patients with advanced melanoma. This is a vaccine against 34 mutated neoantigens, and it showed a significant difference in the recurrence free survival with a hazard ratio of 0.56. And if you look at the 18-month relapse free survival rate, it was 78.6% versus 62.2%. Obviously, these are still fairly early data and numbers are still small. I think we would definitely look forward to the randomized phase 3 study of neoantigen vaccine in melanoma and other cancers. Dr. Pedro Barata: No, absolutely. And I agree, it's really exciting. Dr. Weber did a fantastic job going through some of that data. So let me ask you Dr. Siu, as you think about this cancer vaccine field, what are the limitations that you'd highlight when you think about cancer vaccine development? What challenges do you encounter, obstacles do you encounter?  Dr. Lillian Siu: There are many, many potential challenges. And to some extent, that's probably why cancer vaccine development has been somewhat slow for the many decades until more recently. We know first of all; the target has to be recognized. So we need immunogenic targets. So I think a lot of the effort has been put into trying to understand which antigens expressed by cancer cells are immunogenic, able to activate the immune system. They're obviously assay based methods. You're going to try and see if you can ex vivo stimulate immune cells on dishes and models, etc. But we need to also develop in silico computerized algorithms, and now with AI, I think that makes it even more tangible and exciting that we can actually understand through a large number of neoantigens or other antigens, whether we can choose the ones that are most likely going to actually stimulate T cells to be activated. And I think that is one area that there is a lot of interest in development, how to really develop ways to select out the most attractive antigens.   I would also want to highlight that the platforms, which is how we deliver the vaccine, can also pose significant challenges. For example, vaccines can be delivered using peptide-based formulation, cell-based formulation, nucleic acids and viral vectors. For some of these formulations, for example, the peptides very often are restricted to HLA. They can be rapidly degraded in the body, such that they become not really visible to the T cells anymore. Some of the formulations can be very complex. For example, the cell-base; it may need to have cells isolated from patients, cultured, stored and transported to the site of delivery, which can be very complex. For some of the nucleic acid vaccines, they can have very low transfection efficiency. It could be at risk for also having, for example, DNA vaccines integrated into the host genome. And then lastly, there's also the immune suppressive environment in the TME, such that it does not really have the effect when you give it repeatedly. It becomes attenuated and no longer effective. So these are some of the challenges associated with cancer vaccines.  Dr. Pedro Barata: Thank you for that summary. I think it's really important for folks out there, including researchers getting into this field, to be aware of potential obstacles they might encounter.  So let me ask you the opposite question as we see more compelling preclinical and clinical data emerging in this field of vaccine development, what is really exciting you the most about the newest technologies that are shaping the future of cancer vaccines, in your opinion?  Dr. Lillian Siu: I think one I want to highlight is the immune-modulatory vaccine that Dr. Svane, Dr. Inge Marie Svane had presented during the presentation at ASCO. This is a completely different strategy from the neoantigen vaccine. It targets antigens in the tumor microenvironment. And we know that in the tumor microenvironment, we have tumor cells, we have immune cells, and there are many types of cell types, including, for example, macrophages, cancer associated fibroblasts, regulatory T cells, etc. And using these particular cell types, we know that we can really develop vaccines that can stimulate the body's immune system to attenuate, to downgrade some of the negative factors in the tumor microenvironment. And this is what Dr. Svane and her group is trying to do. For example, they have an IDO vaccine that is able to actually target these antigens in the tumor microenvironment, and by that, not just suppressing the negative forces, so to speak, but also activate T cells to help attack cancer cells. I think that's a very interesting area. Very early promise has been seen already in non-small cell lung cancer in early phase trials using the immune-modulatory vaccine.  But going back to your question, what kind of advances; I mentioned earlier about having novel ways to select our antigens that are most immunogenic. There are many algorithms that are being developed, and I think we can try and leverage that kind of knowledge from artificial intelligence, machine learning. So I think that's definitely very exciting. There are also new vaccine platforms coming out. For example, there's recent data using modification of peptides, so called amphiphile vaccines, that already show very early promise in colorectal cancer, microsatellite status, colorectal cancer, as well as in pancreatic cancer in the molecular residual disease setting, where these long peptide vaccines targeting KRAS mutants together with adjuvant oligonucleotide DNA, combined together, can actually be given to patients and reduce the chance of cancer relapse in patients with resected colorectal cancer, as well as pancreatic cancer, with endpoints such as ctDNA or biomarker being downregulated. I think that's a very exciting example. Another very exciting example is cell-based vaccines that are being developed in Europe by the NKI Netherlands Cancer Institute Group, where they are looking at plasmacytoid dendritic cells that are loaded with peptides from different tumor associated antigens and then given to patients, which, again, in non-small cell lung cancer, together with pembrolizumab, has yielded very high response rate. And we will almost certainly see more trials coming out using that particular platform with the dendritic cells. So that's just some of the examples of exciting things that are happening in the vaccine field. Dr. Pedro Barata: Thank you. I'm wondering if you can share with our listeners about what really are the existing guidelines for using these new tools for discovery, methods of treatment, and perhaps optimizing patient selection to access trials.  Dr. Lillian Siu: To be honest, the latest guideline that was published from the FDA that I can find is almost 13 years ago in 2011. So I think it is time for a new guidance, or at least a draft guidance, to give some additional support and guidance in terms of what to do with these new treatments from the FDA and perhaps other regulatory agencies as well. I think we're now entering a very exciting time that cancer vaccines are no longer an ineffective therapeutic. It is now showing evidence of efficacy, not just in the advanced setting, but also in the molecular residual disease setting. There're so many questions to be answered, like how to develop these trials in early disease; what's the end point? Can we incorporate them into the neoadjuvant setting, and if so, how do we give these drugs before surgery, and do we give them maintenance after surgery? I think guidance from the regulatory authorities would be extremely helpful and informative to guide academic groups as well as the pharmaceutical sector to develop these agents in the right way. Dr. Pedro Barata: Dr. Siu, this is a fantastic summary, and we certainly are on the cusp of a new dawn of discovery and development in cancer vaccines, and super interesting to hear from you talking about it. Before letting you go, do you have any final thoughts that you'd like to share with the listeners, with all of us about this topic? Dr. Lillian Siu: I think as a drug developer like you are, I'm extremely excited because we now have yet another way to leverage the host immunity as a cancer therapeutic, and it is going to be opening a new door to combination therapy because we can imagine combining these treatments with other immunotherapeutics such as bispecific molecules such as CAR Ts and even vaccine plus vaccine combination is feasible. That came up actually during the session as a question from the audience. Can we combine neoantigen vaccines and immune-modulatory vaccines together? And both of our speakers who presented felt that it was possible. Obviously, we have to understand the sequence question and the endpoints question, but the fact that it opens a new door to combinatorial therapy, not just with immunotherapeutics, but perhaps with other therapeutics as well, antibody drug conjugates, etc., really, I think, is very exciting for this field to become further explored.  I mentioned earlier in the podcast that the whole area of cancer prevention is something that we have not been tapping into for the last decade with vaccines because it has not been very effective. Viral vaccines, of course, HPV and other vaccines targeting viruses, but targeting cancer cells is not something we have been successful using vaccines to prevent cancer from developing. I think we would be very interested to see if this will become a reality in the next decade. I think we would start off with patients with high risk of developing cancers such as, as I mentioned earlier, those with lynch syndrome, those harboring BRCA alterations, for example. Can we use these vaccines to actually prevent the cancers from developing in such high-risk individuals? I think the field is definitely open to that consideration.  Dr. Pedro Barata: Definitely. And I'd like to thank you, Dr. Siu, for sharing these great insights with us today on the ASCO Daily News Podcast. Dr. Lillian Siu: Thank you so much for your time.  Dr. Pedro Barata: And thank you to all the listeners for your time today. You'll find a link to the article discussed today in the transcript of this episode, and I encourage you to check out the 2024 ASCO Educational Book. Finally, if you value the insights that you hear on the podcast, please take a moment to rate, review, and subscribe wherever you get your podcasts. So again, thank you so much for your time and see you soon.   Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.   Follow today's speakers:  Dr. Pedro Barata  @PBarataMD  Dr. Lillian Siu  @lillian_siu   Follow ASCO on social media: @ASCO on Twitter ASCO on Facebook ASCO on LinkedIn   Disclosures:    Dr. Pedro Barata: Honoraria: UroToday  Consulting or Advisory Role: Bayer, BMS, Pfizer, EMD Serono, Eisai, Caris Life Sciences, AstraZeneca, Exelixis, AVEO, Dendreon  Speakers' Bureau (Inst): Caris Life Sciences, Bayer, Pfizer/Astellas  Research Funding (Inst.): Blueearth, AVEO, Pfizer, Merck    Dr. Lillian Siu:  Leadership (Immediate family member): Treadwell Therapeutics  Stock and Other Ownership Interests (Immediate family member): Agios   Consulting or Advisory Role: Merck, AstraZeneca/MedImmune, Roche, Voronoi Inc., Oncorus, GSK, Seattle Genetics, Arvinas, Navire, Janpix, Relay Therapeutics, Daiichi Sankyo/UCB Japan, Janssen, Research Funding (Institution): Bristol-Myers Squibb, Genentech/Roche, GlaxoSmithKline, Merck, Novartis, Pfizer, AstraZeneca, Boehringer Ingelheim, Bayer, Amgen, Astellas Pharma, Shattuck Labs, Symphogen, Avid, Mirati Therapeutics, Karyopharm Therapeutics, Amgen

IMSS suma 9.2 millones de derechohabientesBeryl se fortalecerá en el Golfo de México, para cuando llegue a Tamaulipas y TexasWhatsApp tiene nueva función que permite a los usuarios generar imágenes de IAMás información en nuestro podcast

Si te estabas convirtiendo en un vegano financiero, o sea que no comprabas carne porque no te alcanzaba, ahora podrás volver a comer vaca, se trata de un corte especial que no superará los 3 dólares.Escucha la triste historia de un tipo que se ganó 4 millones de dólares en la loteria ¿Qué le pasó? Mantente al día con los últimos de 'El Bueno, la Mala y el Feo'. ¡Suscríbete para no perderte ningún episodio!Ayúdanos a crecer dejándonos un review ¡Tu opinión es muy importante para nosotros!¿Conoces a alguien que amaría este episodio? ¡Compárteselo por WhatsApp, por texto, por Facebook, y ayúdanos a correr la voz!Escúchanos en Uforia App, Apple Podcasts, Spotify, y el canal de YouTube de Uforia Podcasts, o donde sea que escuchas tus podcasts.'El Bueno, la Mala y el Feo' es un podcast de Uforia Podcasts, la plataforma de audio de TelevisaUnivision.

Convidamos novamente o Tiago Reis, analista CNPI e fundador da Suno Research, para participar do podcast. Nesse episódio, falamos sobre o atual momento da bolsa brasileira e quais ações apresentam uma ótima oportunidade. Não perca e deixe seu like! Acompanhe todas as terças e quintas, às 19h, as discussões e temas mais quentes do mercado. O programa, comandado por Bruno Rosolini, recebe analistas e especialistas para trazer todos os detalhes e pontos relevantes de cada assunto para você. Ative as notificações do programa e acompanhe ao vivo!

Kevin Barata is a 46 year old trail ultrarunner who lives in Abbotsford, BC with his wife and three daughters. He has been a police officer with the RCMP for 21 years and currently works with the Emergency Response Team in the Vancouver Lower Mainland. Kevin has been running ultra marathons since 2014 in various distances from 50km to 250 mile races. In fact he recently completed the Coccodona 250 and has run well over 150 miles in multiple backyard ultras. You have also heard us talk about Kevin on the show as the person who provided navigation and a police escort for Dave Proctor as he neared the completion of his record breaking run across Canada.In this episode we talk about how Kevin started running trails and what it takes to train for and complete a 250 mile race.  We discuss how he absolutely loves the challenge that running long distances brings and how he always embraces the journey along the way. Running for Kevin is therapeutic and a way for him to stay grounded and feel accomplished while striving to seek new challenges and surprise himself with what's possible!Connect with Kevin:Instagram: @kbar_runsConnect with Carolyn & Kim:Email us with guest ideas: inspiredsolescast@gmail.comInspired Soles InstagramKim's InstagramKim's FacebookCarolyn's FacebookWe love hearing from you! Connect with us on Instagram @inspiredsolescast or email guest ideas to inspiredsolescast@gmail.com. If you enjoyed this episode, please share it with a friend, subscribe or leave us a rating and review on Apple Podcasts.

basta! chega! é impossível ficar calado com tanta injustiça contra uma barata(o/e) e a gay radpass sub pombinha branca, né? vem desabafar e gritar pelo fim dessas cantigas infantis! Apoie este podcast na ORELO: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://orelo.cc/jogueinogrupo⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Envie seu e-mail para: jogueinogrupo@gmail.com Siga o Joguei no Grupo: ⁠⁠⁠⁠⁠⁠www.instagram.com/jogueinogrupo⁠⁠⁠⁠⁠⁠ Siga o Fabão: ⁠⁠⁠⁠⁠⁠⁠www.instagram.com/eusoufabao⁠⁠⁠⁠⁠⁠⁠ Siga a Jenny Prioli: ⁠⁠⁠⁠⁠⁠⁠www.instagram.com/jennyprioli⁠⁠⁠⁠⁠⁠⁠ Siga o Controle Y: ⁠⁠⁠⁠⁠⁠w⁠ww.instagram.com/controle_y

Federico y Amorós comentan lo sucedido en la corrida de Juan Pedro Domecq con Morante de La Puebla, Alejandro Talavante y Pablo Aguado.

¿Procrasticar es de cagón?: miedos, pensamientos, emociones y un dinosaurio muy retrógrado... Flor con una apertura a puro sahumerio y oráculo y todo sobre como cuidar nuestras mascotas con Filosofía Animal.

Pintó la de filosofar sin saber mucho: karma, verdades y vivir en el cuerpo de otro.... y ¿sale challenge del tema del momento?

Link para hacer donaciones vía PayPal:https://www.paypal.me/julioastilleroCuenta para hacer transferencias a cuenta BBVA a nombre de Julio Hernández López: 1539408017CLABE: 012 320 01539408017 2Tienda:https://julioastillerotienda.com/ Hosted on Acast. See acast.com/privacy for more information.

Dr. Pedro Barata, Director of the Clinical Genitourinary Medical Oncology Research Program at UH Seidman Cancer Center, provides an exclusive round-up of the most groundbreaking and practice-changing research unveiled at the ASCO GU 2024 meeting. With expertise and insight, he delves into pivotal studies such as CheckMate 914 Part B and KEYNOTE-564, exploring their implications for kidney cancer. The episode further unravels the transformative findings from the AMBASSADOR study, shedding light on adjuvant immunotherapy in bladder cancer; genetic testing and FGFR advancements in bladder cancer; life-prolonging therapies and radioligand therapies in castration-resistant prostate cancer; and the latest in minimal residual disease research. Check out Chadi's website for all Healthcare Unfiltered episodes and other content. www.chadinabhan.com/ Watch all Healthcare Unfiltered episodes on YouTube. www.youtube.com/channel/UCjiJPTpIJdIiukcq0UaMFsA

Notas Macabrosas - Jugador de hockey muere tras corte en el cuello con un patín - Xavier Novell, el polémico obispo español que se enamoró de una escritora sobre satanismo y dejó su cargo - Lo que sabemos sobre la reaparición de la ‘niña perro' en Tamaulipas luego de 11 años  - Piloto acusado de intentar apagar los motores de un avión le dijo a la policía que había consumido hongos psicodélicos antes del incidente - La generación que consumió leche radioactiva: liberan expediente Chernobyl-Conasupo  - Una mujer italiana gana un proceso judicial para desalojar a sus dos hijos, de 40 y 42 años  - Escándalo en Canadá por el homenaje a un nazi ucraniano en el Parlamento - Bomberos acuden a una casa por un reporte de incendio y cuando llegan se encuentran con que sólo era decoración de Halloween - Familia demanda a Google alegando que su aplicación Maps llevó a un padre a conducir por un puente derrumbado lo que le costó la vida - Ex alumnos regresan para ayudar a ambulante que les fiaba y prestaba dinero para sus pasajes - El tatuaje de un pandillero revela un crimen sin resolver desde 2004 También puedes escucharnos en Youtube, Spotify, Apple Podcasts, Amazon Music o tu app de podcasts favorita. Apóyanos en Patreon: https://www.patreon.com/leyendaspodcast​ Apóyanos en YouTube: https://www.youtube.com/c/leyendaslegendarias/join Síguenos: https://instagram.com/leyendaspodcast​ https://twitter.com/leyendaspodcast​ https://facebook.com/leyendaspodcast​ #Podcast​ #LeyendasLegendarias​ #HistoriasDelMasAca Learn more about your ad choices. Visit megaphone.fm/adchoices